Infliximab treatment for Crohn's disease
Open Access
- 1 July 2001
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 77 (909), 436-440
- https://doi.org/10.1136/pmj.77.909.436
Abstract
The advent of a therapy that can potentially restore immunological imbalance, modify the disease, and prolong remission in Crohn's disease patients, has thus been eagerly awaited.Keywords
This publication has 36 references indexed in Scilit:
- Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is lowGut, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Risk of lymphoma in inflammatory bowel disease: A population-based estimateGastroenterology, 1998
- Diagnoses of extraintestinal manifestations and cancers in IBD in large population-based databasesGastroenterology, 1998
- Experimental models of inflammatory bowel diseaseGastroenterology, 1995
- StimulusJournal of Clinical Gastroenterology, 1995
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 1992
- Anal complications in Crohn's diseaseDiseases of the Colon & Rectum, 1981